Sharps Technology, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul Kruger Danner
- Full Time Employees
- 55
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 105 Maxess Road Melville NY United States of America 11747
- IPO Date
- Apr 14, 2022
- CIK
- 0001737995
- Website
- sharpstechnology.com
- Similar Companies
- Business
- Sharps Technology, Inc. (NASDAQ: STSS) is a medical device company that designs, develops, manufactures and commercializes innovative safety syringe products and prefillable syringe systems with ultra-low waste features, passive and active needlestick prevention, and reuse prevention mechanisms; its core portfolio includes the SoloGard smart safety syringes (10mL capacity with less than 0.01mL dead space, FDA-, WHO- and CE-approved), SecureGard safety syringes, Provensa premier safety syringes, and advanced copolymer prefillable polymer syringes, supported by end-to-end pharmaceutical services from design to distribution. Founded in 2017 and headquartered in Melville, New York, the company operates a manufacturing facility in Hungary with 500 million units annual capacity and global certifications including ISO and FDA clearance, targeting healthcare providers, pharmaceutical partners and medical supply distributors primarily in the United States and Europe. In recent developments, Sharps Technology completed a five-year sales agreement in 2024 for at least 500 million 10mL SoloGard syringes with a major U.S. medical products supplier, fully utilizing current Hungary plant capacity with initial shipments in late 2024 and phased ramp-up through 2025; enhanced an asset purchase agreement with Nephron Pharmaceuticals for InjectEZ prefillable syringe assets and secured over $200 million in related syringe sales commitments with shipments starting in Q2 2025; exited legacy syringe manufacturing operations; raised over $400 million through a 2025 PIPE financing led by investors including ParaFi, Pantera and Monarq to acquire more than 2 million SOL tokens, establishing the largest publicly traded Solana digital asset treasury strategy with staking partnerships including BONK, Jupiter Exchange and Coinbase; announced a $100 million stock repurchase program; and formed strategic alliances with Pudgy Penguins and New to The Street for media and blockchain exposure.
Sharps Technology Reports Continued Growth in Q1 2026 Highlighting Strengthened Balance Sheet and Strong Treasury Execution
Sharps Technology Adopts Limited Duration Stockholder Rights Plan
Head to Head Survey: TREES (OTCMKTS:CANN) versus Sharps Technology (NASDAQ:STSS)
Financial Survey: Valneva (NASDAQ:VALN) and Sharps Technology (NASDAQ:STSS)
Sharps Technology and BitGo Announce Collaboration to Advance Solana Treasury Strategy
Insider Selling: Sharps Technology (NASDAQ:STSS) Major Shareholder Sells $174,798.00 in Stock
Sharps Technology Strengthens Market Confidence with Advisor Lock-Up Agreement
Head to Head Review: MacroGenics (NASDAQ:MGNX) & Sharps Technology (NASDAQ:STSS)
Sharps Technology Expands Digital Asset Treasury Strategy with Coinbase
Sharps Technology Announces $100 Million Stock Repurchase Program
Crypto.com and Sharps Technology Partner to Strengthen Solana Ecosystem Growth Through Institutional Treasury Solutions
Sharps Technology and Jupiter Exchange Announce Staking Partnership to Accelerate Solana Adoption
Sharps Technology and BONK Announce Staking Collaboration, Bridging Institutional Capital and Web3 Culture
Sharps Technology and Pudgy Penguins Announce Strategic Partnership
Here's why Sharps Technology stock jumped 56% on Wednesday
Sharps Technology, Inc. Announces over $400 Million Private Placement seeking to Establish the Largest Solana Digital Asset Treasury Strategy
Sharps Technology Shares Climb on Latest SoloGard Shipments
Sharps Technology Advances Shipment Under $50 Million SoloGard Supply Agreement and Begins Manufacturing Facility Upgrades
Sharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ET
Sharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ET